Low free and bioavailable testosterone levels may predict pathologically-proven high-risk prostate cancer: a prospective, clinical trial

Basit Öğe Kaydı
dc.authoridOrhan Tanrıverdi / 0000-0002-8105-6254en_US
dc.authoridMuammer Kendirci / 0000-0002-1854-1871en_US
dc.authorscopusidMuammer Kendirci / 8625690500
dc.authorscopusidOrhan Tanrıverdi / 6507392735
dc.authorwosidMuammer Kendirci / AAA-3790-2019
dc.authorwosidOrhan Tanrıverdi / F-2357-2013
dc.contributor.authorBayar, Göksel
dc.contributor.authorŞirin, Hakan
dc.contributor.authorAydın, Mustafa
dc.contributor.authorÖzağarı, Ayşim
dc.contributor.authorTanrıverdi, Orhan
dc.contributor.authorKadıhasanoğlu, Mustafa
dc.contributor.authorKendirci, Muammer
dc.date.accessioned2020-08-30T20:08:05Z
dc.date.available2020-08-30T20:08:05Z
dc.date.issued2017
dc.departmentİstinye Üniversitesi, Tıp Fakültesi, Cerrahi Tıp Bilimleri Bölümüen_US
dc.description.abstractObjective: To determine the predictive value of free and bioavailable testosterone levels on the detection of high-grade prostate cancer proven by histopathological examination of transrectal prostate biopsy specimens. Material and methods: A total of 405 patients who underwent transrectal prostate biopsy due to high prostatic specific antigen (PSA) (>2.5 ng/mL) and/or abnormal findings at digital rectal examination were included in this study. Blood free and bioavailable testosterone levels were calculated by the formula recommended by International Society for the Study of the Aging Male (ISSAM). The patients were stratified according to the D'Amico classification based on PSA levels and histological outcomes of prostate biopsies as benign, low, intermediate and high-risk prostate cancer. Patients were also divided into five groups according to the percentage of cancerous cores. Results: Prostate cancer was detected in 160 of 405 (39.5%) patients. Total, free and bioavailable testosterone levels did not differ significantly between the patients with benign or malign histology. However, mean free (6.2 vs. 5.2 ng/dL, p=0.02) and bioavailable (151 vs. 125 ng/dL, p=0.001) testosterone levels were found to be significantly different in men with low-intermediate and high-risk prostate cancer. Moreover, a significant correlation was found between free, and bioavailable testosterone levels and percentage of cores with cancer (p=0.002 for free and p=0.016 for bioavailable testosterone, respectively). Conclusion: This prospective clinical study demonstrates that reduced levels of calculated blood free and bioavailable testosterone levels are associated with an increased risk of high-grade prostate cancer. Based on these findings blood free and bioavailable testosterone levels may be be thought to be an adjunctive factor in the prediction of high-risk prostate cancer.en_US
dc.identifier.citationBayar, G., Şirin, H., Aydın, M., Özağarı, A., Tanrıverdi, O., Kadıhasanoğlu, M., & Kendirci, M. (2017). Low free and bioavailable testosterone levels may predict pathologically-proven high-risk prostate cancer: a prospective, clinical trial. Turkish journal of urology, 43(3), 289.en_US
dc.identifier.doi10.5152/tud.2017.35467en_US
dc.identifier.endpage296en_US
dc.identifier.issn2149-3235en_US
dc.identifier.issn2149-3057en_US
dc.identifier.issue3en_US
dc.identifier.pmid28861300en_US
dc.identifier.scopus2-s2.0-85043334763en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage289en_US
dc.identifier.urihttps://doi.org/10.5152/tud.2017.35467
dc.identifier.urihttps://hdl.handle.net/20.500.12713/882
dc.identifier.volume43en_US
dc.identifier.wosWOS:000410005000012en_US
dc.identifier.wosqualityN/Aen_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakTR-Dizinen_US
dc.indekslendigikaynakPubMeden_US
dc.institutionauthorTanrıverdi, Orhanen_US
dc.institutionauthorKendirci, Muammeren_US
dc.language.isoenen_US
dc.publisherAvesen_US
dc.relation.ispartofTurkish Journal of Urologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectProstate Canceren_US
dc.subjectProstate-Specific Antigenen_US
dc.subjectRadical Prostatectomyen_US
dc.subjectTestosteroneen_US
dc.subjectTransrectal Prostate Biopsyen_US
dc.titleLow free and bioavailable testosterone levels may predict pathologically-proven high-risk prostate cancer: a prospective, clinical trialen_US
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
H105.pdf
Boyut:
374.6 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
İndir

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
Cerrahi Tıp Bilimleri Bölümü Makale Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
TR-Dizin İndeksli Yayınlar Koleksiyonu